Your browser doesn't support javascript.
loading
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
Vose, Julie M; Fu, Kai; Wang, Lu; Mansoor, Adnan; Stewart, Douglas; Cheng, Hongxia; Smith, Lynette; Yuan, Ji; Qureishi, Hina Naushad; Link, Brian K; Cessna, Melissa H; Barr, Paul M; Kahl, Brad S; Mckinney, Matthew S; Khan, Nadia; Advani, Ranjana H; Martin, Peter; Goy, Andre H; Phillips, Tycel J; Mehta, Amitkumar; Kamdar, Manali; Crump, Michael; Pro, Barbara; Flowers, Christopher R; Jacobson, Caron A; Smith, Sonali M; Stephens, Deborah M; Bachanova, Veronika; Jin, Zhaohui; Wu, Shishou; Hernandez-Ilizaliturri, Francisco; Torka, Pallawi; Anampa-Guzmán, Andrea; Kashef, Farshid; Li, Xing; Sharma, Sunandini; Greiner, Timothy C; Armitage, James O; Lunning, Matthew; Weisenburger, Dennis D; Bociek, Robert G; Iqbal, Javeed; Yu, Guohua; Bi, Chengfeng.
Afiliação
  • Vose JM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
  • Fu K; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Wang L; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Mansoor A; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China.
  • Stewart D; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
  • Cheng H; Departments of Oncology and Medicine, University of Calgary, Calgary, Canada.
  • Smith L; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Yuan J; Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
  • Qureishi HN; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
  • Link BK; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Cessna MH; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Barr PM; Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
  • Kahl BS; Department of Pathology, Intermountain Medical Center, Murray, UT, USA.
  • Mckinney MS; Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
  • Khan N; Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Advani RH; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
  • Martin P; Department of Hematology/Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Goy AH; Division of Oncology, Stanford Cancer Institute, Stanford, CA, USA.
  • Phillips TJ; Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.
  • Mehta A; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Kamdar M; Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Crump M; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Pro B; Division of Hematology, University of Colorado, Denver, CO, USA.
  • Flowers CR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada.
  • Jacobson CA; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA.
  • Smith SM; Division of Cancer Medicine, Department of Lymphoma-Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
  • Stephens DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Bachanova V; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Jin Z; Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, USA.
  • Wu S; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Hernandez-Ilizaliturri F; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Torka P; Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, No.20 Yuhuangding East Road, Yantai, 264000, China.
  • Anampa-Guzmán A; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Kashef F; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Li X; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Sharma S; Department of Pathology, University at Buffalo, Buffalo, NY, USA.
  • Greiner TC; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Armitage JO; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Lunning M; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Weisenburger DD; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
  • Bociek RG; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
  • Iqbal J; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Yu G; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
  • Bi C; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
J Hematol Oncol ; 16(1): 122, 2023 12 16.
Article em En | MEDLINE | ID: mdl-38104096
ABSTRACT

BACKGROUND:

Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of this disease. This study aims to investigate the clinical and pathological features of MCL in the immunochemotherapy era and improve the prognostic models for a more accurate prediction of patient outcomes.

METHODS:

The North American Mantle Cell Lymphoma Project is a multi-institutional collaboration of 23 institutions across North America to evaluate and refine prognosticators for front-line therapy. A total of 586 MCL cases diagnosed between 2000 and 2012 are included in this study. A comprehensive retrospective analysis was performed on the clinicopathological features, treatment approaches, and outcomes of these cases. The establishment of novel prognostic models was based on in-depth examination of baseline parameters, and subsequent validation in an independent cohort of MCL cases.

RESULTS:

In front-line strategies, the use of hematopoietic stem cell transplantation was the most significant parameter affecting outcomes, for both overall survival (OS, p < 0.0001) and progression-free survival (PFS, p < 0.0001). P53 positive expression was the most significant pathological parameter correlating with inferior outcomes (p < 0.0001 for OS and p = 0.0021 for PFS). Based on the baseline risk factor profile, we developed a set of prognostic models incorporating clinical, laboratory, and pathological parameters that are specifically tailored for various applications. These models, when tested in the validation cohort, exhibited strong predictive power for survival and showed a stratification resembling the training cohort.

CONCLUSIONS:

The outcome of patients with MCL has markedly improved over the past two decades, and further enhancement is anticipated with the evolution of clinical management. The innovative prognostic models developed in this study would serve as a valuable tool to guide the selection of more suitable treatment strategies for patients with MCL.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Célula do Manto País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Célula do Manto País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos